There has been a marked increase in the use of these medications since they were first approved for weight loss in 2014, particularly following the approval of Wegovy in 2021 and Zepbound in 2022
As with any medication purchase, verify pharmacy credentials and discuss with your prescriber before switching sources
These steps ensure compliance and protect patients
Taking both together increases the risk of tachycardia, hypertension, and potentially dangerous drug interactions, especially in people with pre-existing heart conditions, arrhythmias, or uncontrolled high blood pressure
Clinical data suggests roughly 75% of weight lost consists of fat mass with 25% from lean tissue
Regular follow-up schedule during maintenance therapy typically includes: Clinical visits every 3-6 months to assess weight trends, side effects, and comorbidity status Laboratory monitoring as clinically indicated (lipid panel, hemoglobin A1c if diabetic, liver function tests if indicated) Blood pressure monitoring given expected improvements with weight loss Nutritional assessment to ensure adequate protein and micronutrient intake during weight loss Patients should be empowered to contact their healthcare provider between scheduled visits if concerning symptoms develop, including persistent gastrointestinal symptoms, signs of gallbladder disease, severe abdominal pain, or symptoms of hypoglycemia